Navigation Links
0209 VixOne Nebulizer

Products0209 VixOne Nebulizer
Company Westmed
Item 0209 VixOne Nebulizer
Features 
  • Nebulizer
  • Mouthpiece
  • Universal T
  • 7' Kink Resistant Tubing w/Threaded Nut & Flexhose
  • High output nebulizer which delivers medication quickly and efficiently
  • Ideal particle size production (MMAD=2.7 µ) allowing high lung deposition which results in maximum therapeutic effect.
  • Anti-spill Tee design
  • Leak-proof and secure seal with simple 1/4 turn assembly design
  • Very low dead volume (0.7cc)
  • High medication bowl capacity (13cc)
  • Graduated volume (cc) markings on bowl
  • Nebulizes in upright positions or at angles up to 45°
  • Latex Free
  • 50 per case
Description Innovators in Anesthesia and Respiratory Products

Westmed designs, manufacturers and markets leading quality medical devices for Anesthesia and Respiratory professionals. Our mission is to design and manufacture products that enhance the clinician's ability to deliver quality medical care while paying close attention to the bottom line.

Our web site is designed with our customers in mind. The Westmed web site will link you to our company, our people and our products. Like the clinicians we serve, Westmed is dedicated in our pursuit of excellence and enhancing healthcare for all of us.

Aerosol Delivery: From our high efficiency continuous Heart ® Nebulizers to the protection and high concentration of Circulaire ®, Westmed has a nebulizer for all of your needs.
Info Westmed
Customer Service: (800) 724-2328
Web site: http://westmedinc.com/

Related medicine products :

1. 0237 VixOne Infant Nebulizer Kit
2. 0236 VixOne Infant Nebulizer Kit
3. VixOne Infant Extension Set
4. 0207 VixOne Nebulizer
5. 0215 VixOne Nebulizer
6. 0217 VixOne Nebulizer
7. 0210 VixOne Nebulizer
8. 0310 VixOne Nebulizer
9. 0222 VixOne Nebulizer
10. 0311 VixOne Nebulizer
11. 0312 VixOne Nebulizer
Breaking Medicine News(10 mins):Health News:Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative 2Health News:Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative 3Health News:Wellness Manufacturer Wins Two 2009 American Spa Awards 2Health News:Obesity and Inactivity -- The Biggest Threat to the Nation's Health 2Health News:Obesity and Inactivity -- The Biggest Threat to the Nation's Health 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 2Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 4Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 5Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 6Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 7Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 8Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 9Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 10Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 11Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 3Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 4Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 5
Breaking Medicine Technology:CompuCyte Announces the Release of Four-Laser Imaging Cytometers 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 1DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 2DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 3DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 4DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 5DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 6DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 7DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 8DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 9DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 10DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 11DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 12DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 13Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 1Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 2Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 3Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 4Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 5Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 6Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 7Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 8Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 9Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 10Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 11Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 12Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 13Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 14Dr James OConnell Named J H Kanter Prize Laureate 54148 1Dr James OConnell Named J H Kanter Prize Laureate 54148 2Dr James OConnell Named J H Kanter Prize Laureate 54148 3